Cytokinetics Inc. (CYTK)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.56 (+1.11%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Cytokinetics Inc. (CYTK)
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Key Insights

Critical company metrics and information
  • Share Price

    $50.96
  • Market Cap

    $6.01 Billion
  • Total Outstanding Shares

    118.01 Million Shares
  • Total Employees

    564
  • Dividend

    No dividend
  • IPO Date

    April 29, 2004
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.cytokinetics.com

Historical Stock Splits

If you bought 1 share of CYTK before June 25, 2013, you'd have 0.17 shares today.
Execution DateSplit Amount
June 25, 20131-for-6 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-52.70 Million
Net Cash Flow From Financing Activities$1.10 Billion
Net Cash Flow From Operating Activities, Continuing$-404.36 Million
Net Cash Flow$-52.80 Million
Net Cash Flow From Financing Activities, Continuing$1.10 Billion
Exchange Gains/Losses$103000.00
Net Cash Flow From Investing Activities$-745.37 Million
Net Cash Flow From Investing Activities, Continuing$-745.37 Million
Net Cash Flow From Operating Activities$-404.36 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Diluted Average Shares$329707.00
Research and Development$330.75 Million
Income/Loss From Continuing Operations After Tax$-576.40 Million
Costs And Expenses$546.73 Million
Basic Earnings Per Share$5.38
Net Income/Loss Attributable To Parent$-576.40 Million
Benefits Costs and Expenses$275.05 Million
Nonoperating Income/Loss$44.11 Million
Income/Loss From Continuing Operations Before Tax$-415.39 Million
Net Income/Loss Available To Common Stockholders, Basic$-576.40 Million
Diluted Earnings Per Share$5.38
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Revenues$3.22 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Basic Average Shares$110790.00
Operating Income/Loss$-524.63 Million
Operating Expenses$527.85 Million
Net Income/Loss$-576.40 Million
Other Operating Expenses$197.09 Million
Interest Expense, Operating$35.93 Million
Preferred Stock Dividends And Other Adjustments$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Liabilities$1.34 Billion
Liabilities And Equity$1.44 Billion
Equity$-13.91 Million
Accounts Payable$11.58 Million
Fixed Assets$64.22 Million
Current Assets$1.02 Billion
Other Non-current Assets$353.24 Million
Other Current Liabilities$70.35 Million
Long-term Debt$619.95 Million
Wages$27.88 Million
Equity Attributable To Parent$-13.91 Million
Equity Attributable To Noncontrolling Interest$0.00
Cash$1.30 Billion
Current Liabilities$109.81 Million
Noncurrent Assets$417.46 Million
Liabilities$1.45 Billion
Assets$1.44 Billion
Other Non-current Liabilities$720.21 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.